INHIBRX LP has a total of 59 patent applications. It decreased the IP activity by 75.0%. Its first patent ever was published in 2012. It filed its patents most often in China, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and biotechnology are PIERIS PROTEOLAB AG, ARGEN-X N V and DAVIES JULIAN.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 6 | |
#2 | United States | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 6 | |
#4 | EPO (European Patent Office) | 5 | |
#5 | Singapore | 5 | |
#6 | Brazil | 4 | |
#7 | Canada | 4 | |
#8 | Hong Kong | 4 | |
#9 | Republic of Korea | 4 | |
#10 | Mexico | 4 | |
#11 | Israel | 2 | |
#12 | Argentina | 1 | |
#13 | Australia | 1 | |
#14 | Hungary | 1 | |
#15 | Montenegro | 1 | |
#16 | New Zealand | 1 | |
#17 | Serbia | 1 | |
#18 | Taiwan | 1 | |
#19 | Ukraine | 1 | |
#20 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Deveraux Quinn | 48 |
#2 | Eckelman Brendan P | 40 |
#3 | Timmer John C | 40 |
#4 | Razai Amir S | 16 |
#5 | Hussain Abrahim | 16 |
#6 | Jones Kyle S | 16 |
#7 | Willis Katelyn M | 11 |
#8 | Nguy Peter L | 11 |
#9 | Eckelman Brendan | 8 |
#10 | Timmer John | 8 |
Publication | Filing date | Title |
---|---|---|
CN107922491A | The fusion protein of multivalence and polyspecific combination DR5 | |
EP3247407A1 | Non-immunogenic single domain antibodies | |
BR112017008525A2 | isolated fusion protein, and methods for treating or alleviating a symptom of a disease or disorder, for treating or alleviating an inflammation or symptom of an inflammatory disease or disorder, and for reducing the risk of infection in an individual. | |
US2015104410A1 | Serpin fusion polypeptides and methods of use thereof |